https://www.selleckchem.com/products/en450.html
1-18.1) for tacrolimus and 9.01% (95%CI 6.2-12.8) for MMF. Pooled biochemical remission rates for tacrolimus and MMF in patients with intolerance to standard therapy were 56.6% (CI 43.4-56.6) 73.5% (CI 58.1-84.7), and among non-responders were 59.1% (CI 48.7-68.8) 40.8% (CI 32.3-50., respectively. Moreover, the overall quality assessments using GRADE proved to be very low for all our outcomes in both treatment groups. Tacrolimus and MMF are in practice considered effective for patients with AIH who are non-responders or intolerant to fi
Like
Comment
Share
